Pulmonary sarcoidosis: CT assessment of lesion reversibility.

Brauner, M.; Lenoir, S.; Greniér, Philippe; Cluzel, Philippe; Battesti, J P; Valeyre, Dominique

doi:10.1148/radiology.182.2.1732948

Cited by 126 publications

(87 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alveolar consolidation, nodularity and a ground glass pattern on CT scanning have recently been shown to indicate reversible disease in sarcoidosis [11]; in our patient, a prominent ground glass appearance was seen on CT, but not on chest radiography. In most patients with uncomplicated pulmonary sarcoidosis, CT scanning adds little to management; a response to therapy is the rule and CT scanning, which is expensive and carries a significant radiation burden, cannot be justified.…”

Section: Discussionsupporting

confidence: 40%

Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning

O’Callaghan¹,

Wells²,

Lalvani³

et al. 1994

Eur Respir J

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 40%

Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning

O’Callaghan¹,

Wells²,

Lalvani³

et al. 1994

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…12 15 16 Agreement in identifying reversible disease on HRCT scans was good (k = 0.61). Studies have established that parenchymal consolidation, 17 nodules, [18][19][20] and ground glass opacity not associated with traction bronchiectasis or bronchiolectasis 21 are signs of reversible lung disease. The good kappa value indicates that radiologists are aware of, and agreed on, the features of disease reversibility on the HRCT scan.…”

Section: Discussionmentioning

confidence: 99%

HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation

Aziz

Wells²,

Hansell³

et al. 2004

Thorax

174

104

View full text Add to dashboard Cite

Background: This study was designed to measure inter-observer variation between thoracic radiologists in the diagnosis of diffuse parenchymal lung disease (DPLD) using high resolution computed tomography (HRCT) and to identify areas of difficulty where expertise, in the form of national panels, would be of particular value. Methods: HRCT images of 131 patients with DPLD (from a tertiary referral hospital (n = 66) and regional teaching centres (n = 65)) were reviewed by 11 thoracic radiologists. Inter-observer variation for the first choice diagnosis was quantified using the unadjusted kappa coefficient of agreement. Observers stated differential diagnoses and assigned a percentage likelihood to each. A weighted kappa was calculated for the likelihood of each of the six most frequently diagnosed disease entities. Results: Observer agreement on the first choice diagnosis was moderate for the entire cohort (k = 0.48) and was higher for cases from regional centres (k = 0.60) than for cases from the tertiary referral centre (k = 0.34). 62% of cases from regional teaching centres were diagnosed with high confidence and good observer agreement (k = 0.77). Non-specific interstitial pneumonia (NSIP) was in the differential diagnosis in most disagreements (55%). Weighted kappa values quantifying the likelihood of specific diseases were moderate to good (mean 0.57, range 0.49-0.70). Conclusion: There is good agreement between thoracic radiologists for the HRCT diagnosis of DPLD encountered in regional teaching centres. However, cases diagnosed with low confidence, particularly where NSIP is considered as a differential diagnosis, may benefit from the expertise of a reference panel.

show abstract

“…Many research groups have investigated CT as a non invasive examination in distinguishing patients with active disease and potentially reversible lesionsfrom those with irreversible fibrotic disease [26][27][28]. Results of these studies though seem to be inconsistent [19,16,[28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Clearance of technetium-99m-DTPA in pulmonary sarcoidosis

Αντωνίου

Tzanakis

Malagari

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Background. The aim of this study was to explore the possible association of the lung clearance of 99mTc- DTPA scan with HRCT lung abnormalities and with the pulmonary function tests [PFTs] in patients with sarcoidosis. Methods. We studied prospectively 15 patients [5 males, 10 females] of median age 46yr [range 27-67] with histologically proved sarcoidosis. HRCT scoring included the sum of the severity and extent of lymph node enlargement and parenchymal involvement. Results. The mean DTPA clearance half-time [τ 1/2 <40 min] was found [mean [SD]] 38.3+4.5min. The lymph node enlargement was found 34% and the parenchymal involvement 12%. DTPA clearance was negatively correlated with the parenchymal involvement [r= -0.651, p=0.009]. The HRCT parenchymal abnormalities were found significantly correlated with PFTs [FVC [r= -0.65, p=0.008] and TLCO [r= -0.76, p=0.02]. Conclusions. Our data suggest a moderate association between 99mTc-DTPA scan and HRCT in pulmonary sarcoidosis. However, further studies in large scale of sarcoid patients are needed to clarify the role of this novel methodology in the evaluation and follow-up of this disorder.

show abstract

Pulmonary sarcoidosis: CT assessment of lesion reversibility.

Cited by 126 publications

References 0 publications

Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning

Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning

HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation

Clearance of technetium-99m-DTPA in pulmonary sarcoidosis

Contact Info

Product

Resources

About